MX2011009503A - Composiciones que comprenden una mezcla de aceite de acido graso y un tensioactivo, y metodos y usos de las mismas. - Google Patents
Composiciones que comprenden una mezcla de aceite de acido graso y un tensioactivo, y metodos y usos de las mismas.Info
- Publication number
- MX2011009503A MX2011009503A MX2011009503A MX2011009503A MX2011009503A MX 2011009503 A MX2011009503 A MX 2011009503A MX 2011009503 A MX2011009503 A MX 2011009503A MX 2011009503 A MX2011009503 A MX 2011009503A MX 2011009503 A MX2011009503 A MX 2011009503A
- Authority
- MX
- Mexico
- Prior art keywords
- surfactant
- fatty acid
- oil mixture
- acid oil
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
- 229930195729 fatty acid Natural products 0.000 title abstract 2
- 239000000194 fatty acid Substances 0.000 title abstract 2
- 150000004665 fatty acids Chemical class 0.000 title abstract 2
- 239000004094 surface-active agent Substances 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 abstract 3
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 125000004494 ethyl ester group Chemical group 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
Abstract
La presente invención se refiere a un preconcentrado que comprende una mezcla de aceite de ácido graso que contiene EPA y DHA, preferiblemente en la forma de éster etíli.co o triglicérido, y al menos un tensioactivo. Los preconcentrados son capaces de formar un sistema de suministro de fármaco auto-nanoemulsificable, un sistema de suministro de fármaco auto-microemulsificable o un sistema de suministro de fármaco auto-emulsificable (SNEDDS, SMEDDS o SEDDS) en una solución acuosa. La solicitud también se dirige a un preconcentrado de suplemento alimenticio.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15861309P | 2009-03-09 | 2009-03-09 | |
US24263009P | 2009-09-15 | 2009-09-15 | |
US25429109P | 2009-10-23 | 2009-10-23 | |
US25429309P | 2009-10-23 | 2009-10-23 | |
PCT/IB2010/000824 WO2010103404A1 (en) | 2009-03-09 | 2010-03-09 | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011009503A true MX2011009503A (es) | 2011-09-28 |
Family
ID=42727856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011009503A MX2011009503A (es) | 2009-03-09 | 2010-03-09 | Composiciones que comprenden una mezcla de aceite de acido graso y un tensioactivo, y metodos y usos de las mismas. |
Country Status (17)
Country | Link |
---|---|
US (6) | US11395811B2 (es) |
EP (4) | EP2405902B1 (es) |
JP (4) | JP6176894B2 (es) |
KR (3) | KR101966874B1 (es) |
CN (3) | CN110538148A (es) |
AU (1) | AU2010222648B2 (es) |
BR (1) | BRPI1009431A2 (es) |
CA (2) | CA2754860C (es) |
CO (1) | CO6501136A2 (es) |
EA (1) | EA022028B1 (es) |
ES (2) | ES2894340T3 (es) |
IL (1) | IL215043A (es) |
MX (1) | MX2011009503A (es) |
NZ (1) | NZ595204A (es) |
PH (1) | PH12019500030A1 (es) |
SG (1) | SG174314A1 (es) |
WO (3) | WO2010119319A1 (es) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11395811B2 (en) * | 2009-03-09 | 2022-07-26 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture comprising EPA and DHA in free acid form and a surfactant, and methods and uses thereof |
US8207363B2 (en) | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
BRPI1014405A2 (pt) | 2009-04-29 | 2016-04-05 | Amarin Corp Plc | composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso |
EP3797591A1 (en) | 2009-04-29 | 2021-03-31 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
KR20120016677A (ko) | 2009-06-15 | 2012-02-24 | 아마린 파마, 인크. | 병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법 |
SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
EP2488022B1 (en) | 2009-10-16 | 2018-01-10 | Mochida Pharmaceutical Co., Ltd. | Compositions |
JP6116905B2 (ja) * | 2009-10-23 | 2017-04-19 | プロノヴァ・バイオファーマ・ノルゲ・アーエスPronova BioPharma Norge AS | 脂肪酸油混合物の被覆型カプセル剤および錠剤 |
BR112012011478B1 (pt) | 2009-10-29 | 2021-12-21 | Acasti Pharma, Inc | Composições fosfolipídicas terapêuticas concentradas e uso das referidas composições |
EP2519332B1 (en) | 2009-12-30 | 2014-03-05 | BASF Pharma (Callanish) Limited | Simulated moving bed chromatographic separation process for the purification of polyunsaturated fatty acids |
CN102884201B (zh) | 2010-01-19 | 2016-04-13 | 帝斯曼知识产权资产管理有限公司 | 生产二十碳五烯酸的微生物、脂肪酸组成物及其制作方法与用途 |
US11236351B2 (en) | 2010-05-17 | 2022-02-01 | Dow Agrosciences Llc | Production of DHA and other LC PUFAs in plants |
KR20130139896A (ko) * | 2010-09-08 | 2013-12-23 | 프로노바 바이오파마 너지 에이에스 | 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물 |
JP2013537186A (ja) * | 2010-09-08 | 2013-09-30 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂肪酸油混合物と遊離脂肪酸とスタチンとを含む組成物 |
WO2012032414A2 (en) * | 2010-09-08 | 2012-03-15 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture, a surfactant, and a statin |
AU2011324909B2 (en) * | 2010-11-05 | 2016-09-08 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US20120302639A1 (en) * | 2011-02-16 | 2012-11-29 | Pivotal Therapeutics Inc. | Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death |
EP2675443A1 (en) * | 2011-02-16 | 2013-12-25 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid diagniostic assay for the dietary management of patients with cardiovascular disease (cvd) |
WO2012112531A1 (en) * | 2011-02-16 | 2012-08-23 | Pivotal Therapeutics, Inc. | Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
EP2675446A1 (en) * | 2011-02-16 | 2013-12-25 | Pivotal Therapeutics, Inc. | Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US9119826B2 (en) * | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
WO2012112511A1 (en) * | 2011-02-16 | 2012-08-23 | Pivotal Therapeutics, Inc. | Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events |
US8697676B2 (en) * | 2011-06-15 | 2014-04-15 | Ronald E Rosedale | Omega-3 fatty acid nutriceutical composition and optimization method |
US10383839B2 (en) | 2011-06-30 | 2019-08-20 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
GB201111589D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New modified process |
GB201111601D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New process |
GB201111594D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New improved process |
GB201111591D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Further new process |
GB201111595D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Improved process |
TWI582235B (zh) | 2011-07-21 | 2017-05-11 | Dsm智慧財產有限公司 | 生產二十碳五烯酸之微生物、脂肪酸組成物及其製作方法與用途 |
WO2013013210A1 (en) * | 2011-07-21 | 2013-01-24 | Dsm Ip Assets B.V. | Microbial oils enriched in polyunsaturated fatty acids |
TW201307553A (zh) | 2011-07-26 | 2013-02-16 | Dow Agrosciences Llc | 在植物中生產二十二碳六烯酸(dha)及其他長鏈多元不飽和脂肪酸(lc-pufa)之技術 |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013072767A1 (en) * | 2011-11-18 | 2013-05-23 | Pronova Biopharma Norge As | Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
PT2800563T (pt) | 2012-01-06 | 2018-11-07 | Chrysalis Pharma Ag | Composições enriquecidas com dpa de ácidos gordos omega-3 polinsaturados sob a forma de ácido livre |
AU2013235266B2 (en) | 2012-03-20 | 2017-10-19 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
EP3072510B1 (en) * | 2012-03-30 | 2019-05-08 | Micelle BioPharma, Inc. | Omega-3 fatty acid ester compositions |
US20160228397A1 (en) * | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
US20150132389A1 (en) * | 2012-03-30 | 2015-05-14 | Sancilio & Company, Inc. | Omega-3 Fatty Acid Ester Compositions |
US20150125529A1 (en) * | 2012-03-30 | 2015-05-07 | Sancilio & Company, Inc. | Omega-3 Fatty Acid Ester Compositions |
US9480651B2 (en) * | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
KR20150028233A (ko) | 2012-05-07 | 2015-03-13 | 옴테라 파마슈티칼스, 인크. | 스타틴 및 오메가-3 지방산의 조성물 |
KR20220140655A (ko) * | 2012-05-14 | 2022-10-18 | 닛폰 스이산 가부시키가이샤 | 환경 오염 물질을 저감시킨 고도 불포화 지방산 또는 고도 불포화 지방산 에틸에스테르 및 그 제조 방법 |
EP2861227A4 (en) * | 2012-06-17 | 2016-01-27 | Matinas Biopharma Inc | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
US20140194512A1 (en) * | 2012-06-17 | 2014-07-10 | Matinas Biopharma, Inc. | Compositions comprising docosapentaenoic acid and methods of use |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
CN103015230B (zh) * | 2012-11-27 | 2015-04-01 | 广州嘉德乐生化科技有限公司 | 一种单硬脂酸甘油酯和聚氧乙烯醚脂肪酸皂的组合物 |
JP6881893B2 (ja) * | 2012-12-06 | 2021-06-02 | マティナス バイオファーマ インコーポレイテッド | ω3ペンタエン酸組成物および使用方法 |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
GB201300354D0 (en) | 2013-01-09 | 2013-02-20 | Basf Pharma Callanish Ltd | Multi-step separation process |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
ES2748562T3 (es) | 2013-02-28 | 2020-03-17 | Basf As | Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y procedimientos de uso de la misma |
WO2014143275A1 (en) * | 2013-03-13 | 2014-09-18 | Matinas Biopharma Inc. | Omega-3 pentaenoic acid compositions and methods of use |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
WO2014179325A1 (en) * | 2013-04-29 | 2014-11-06 | Matinas Biopharma, Inc. | Omega-3 fatty acid formulations for use as pharmaceutical treatment |
US9428711B2 (en) | 2013-05-07 | 2016-08-30 | Groupe Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
US8802880B1 (en) | 2013-05-07 | 2014-08-12 | Group Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
ES2841344T3 (es) * | 2013-07-18 | 2021-07-08 | Mochida Pharm Co Ltd | Composición autoemulsionante de ácidos grasos omega-3 |
ES2817527T3 (es) | 2013-07-18 | 2021-04-07 | Mochida Pharm Co Ltd | Composición autoemulsionante de ácidos grasos omega-3 |
WO2015011724A2 (en) * | 2013-07-22 | 2015-01-29 | Kms Health Center Pvt Ltd | A novel omega -3 fatty acid composition with a plant extract |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
EP2883860B1 (fr) | 2013-12-11 | 2016-08-24 | Novasep Process | Procédé chromatographique de production d'acides gras polyinsaturés |
JP6501416B2 (ja) | 2013-12-20 | 2019-04-17 | マラ リニューアブルズ コーポレーション | 微生物から油を回収する方法 |
WO2015104464A1 (fr) | 2014-01-07 | 2015-07-16 | Novasep Process | Procédé de purification d'acides aminés aromatiques |
CN105939705B (zh) * | 2014-01-28 | 2020-03-17 | 费森尤斯卡比德国有限公司 | 用于肠胃外给药的包含epa甘油三酯和dha甘油三酯的组合物 |
IN2014CH01872A (es) | 2014-04-09 | 2015-05-08 | Nanoceutica Lab Pvt Ltd | |
EP3906920A1 (en) * | 2014-06-06 | 2021-11-10 | Marine Ingredients, LLC | Omega-3 compositions, dosage forms, and methods of use |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
RU2712142C2 (ru) * | 2014-11-05 | 2020-01-24 | Эбботт Лабораторис Гмбх | Способы получения композиций с улучшенным профилем безопасности, содержащих панкреатин, и композиции, пригодные для фармацевтического применения |
CN105614638A (zh) * | 2014-11-28 | 2016-06-01 | 深圳市前海安测信息技术有限公司 | Dha纳米乳及其制备方法和其在健康保健饮品中的应用 |
US10561627B2 (en) * | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
US11007161B1 (en) * | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
JP6514720B2 (ja) | 2015-01-21 | 2019-05-15 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
CN107922308A (zh) * | 2015-06-02 | 2018-04-17 | 日东药品工业株式会社 | 新型甘油三酯及其用途 |
RU2655803C2 (ru) * | 2016-03-10 | 2018-05-29 | АД Смарт, СИА | Фармацевтическая композиция для профилактики и лечения атеросклероза |
JP6738477B2 (ja) * | 2016-03-16 | 2020-08-12 | ゴールデン オメガ ノルウェー アーエス | ω−3脂肪酸誘導体を含む粉末及び錠剤、ならびにその製造方法 |
US10851395B2 (en) | 2016-06-10 | 2020-12-01 | MARA Renewables Corporation | Method of making lipids with improved cold flow properties |
CN106072611A (zh) * | 2016-06-20 | 2016-11-09 | 威海百合生物技术股份有限公司 | 一种含不饱和脂肪酸的多相稀释组合物 |
GB201611920D0 (en) * | 2016-07-08 | 2016-08-24 | Astrazeneca Ab | Pharmaceutical compositions |
WO2018054265A1 (zh) * | 2016-09-20 | 2018-03-29 | 张碧婷 | 亲水性脂类组合物的包装组合物,其制备及调配方法和应用 |
CN107048405A (zh) * | 2017-03-03 | 2017-08-18 | 武汉锶博睿医药技术有限公司 | 脂肪酸组件微胶囊及其制备方法 |
GR1009542B (el) | 2018-04-25 | 2019-06-07 | Φαρματεν Α.Β.Ε.Ε. | Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων |
EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
PT4056176T (pt) | 2018-09-24 | 2024-05-27 | Amarin Pharmaceuticals Ie Ltd | Métodos de redução do risco de eventos cardiovasculares num indivíduo |
EP3886908A1 (en) | 2018-11-30 | 2021-10-06 | Evonik Operations GmbH | Preparation comprising a dispersion of phospholipids and fatty acid salts |
MX2021012572A (es) | 2019-04-18 | 2022-01-18 | Akershus Univ Hf | Terapia de combinacion que comprende un agonista de ffar4 y un agonista de nachr alfa-7 o modulador positivo. |
KR102096391B1 (ko) * | 2019-10-11 | 2020-04-06 | (주)아이엠디팜 | 액상결정 구조체를 형성하는 오메가-3-지방산 조성물 |
CN110584084A (zh) * | 2019-10-17 | 2019-12-20 | 广州白云山汉方现代药业有限公司 | 一种乳化稳定剂及含该乳化稳定剂的营养乳液 |
CN113827547A (zh) * | 2020-06-23 | 2021-12-24 | 南京清普生物科技有限公司 | 一种缓释制剂组合物 |
CN111729125B (zh) * | 2020-07-31 | 2022-10-04 | 陕西佰傲再生医学有限公司 | 骨止血材料 |
JP2021008518A (ja) * | 2020-10-21 | 2021-01-28 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
CN116407543A (zh) * | 2021-12-29 | 2023-07-11 | 中国科学院上海药物研究所 | Epa-ee纳米脂质组合物、及其制剂、制备方法和应用 |
KR20230161551A (ko) * | 2022-05-18 | 2023-11-28 | 부광약품 주식회사 | 제제학적으로 안정성이 향상된 연질 캡슐 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5312473B1 (es) | 1971-05-24 | 1978-05-01 | ||
GB2033745B (en) | 1978-05-26 | 1983-08-17 | Wellcome Found | Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions |
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
AU552068B2 (en) * | 1981-09-21 | 1986-05-22 | Asama Chemical Co. Ltd. | Preservation of edible oils |
ATE55056T1 (de) | 1982-12-09 | 1990-08-15 | Advanced Drug Tech | Einfach absorbierbare fettsaeureemulsionen. |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4843095A (en) * | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US5035896A (en) | 1988-06-15 | 1991-07-30 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
WO1991002520A1 (en) | 1989-08-17 | 1991-03-07 | Cortecs Limited | Pharmaceutical formulations |
US5532002A (en) * | 1989-08-17 | 1996-07-02 | Cortecs Limited | Gelatin pharmaceutical formulations |
CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5501077A (en) * | 1994-05-27 | 1996-03-26 | Springwell Dispensers, Inc. | Thermoelectric water chiller |
JPH0889167A (ja) | 1994-09-27 | 1996-04-09 | Nippon Oil & Fats Co Ltd | 多価不飽和脂肪酸含有醗酵乳の製造方法 |
MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
GB9509764D0 (en) | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
DE19608137A1 (de) * | 1996-03-02 | 1997-09-04 | Meyer Lucas Gmbh & Co | Lipid-Zubereitungen für diätetische Zwecke |
AU1509799A (en) | 1997-12-05 | 1999-06-28 | Chong Kun Dang Corporation | Pharmaceutical composition containing cyclosporin |
WO1999029300A1 (en) | 1997-12-10 | 1999-06-17 | Rtp Pharma Inc. | Self-emulsifying fenofibrate formulations |
EP1039893B1 (en) | 1997-12-10 | 2011-02-02 | Cyclosporine Therapeutics Limited | Pharmaceutical compositions containing an omega-3 fatty acid oil |
WO1999056727A2 (en) | 1998-05-07 | 1999-11-11 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
US20050037065A1 (en) | 1999-05-27 | 2005-02-17 | Drugtech Corporation | Nutritional formulations |
ES2246769T3 (es) | 2000-05-22 | 2006-03-01 | Pro Aparts - Investimentos E Consultoria Lda | Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico. |
EP1279400A1 (en) * | 2001-07-25 | 2003-01-29 | Target Hit sa | Modifying the fatty acid composition of cell membranes of organs and tissues |
KR100441167B1 (ko) | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | 마이크로에멀젼 예비 농축액 조성물 |
ITMI20020269A1 (it) * | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
GB0210212D0 (en) | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
ITMI20022511A1 (it) | 2002-11-26 | 2004-05-27 | Victorix Assets Ltd | Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale. |
US20040254357A1 (en) | 2002-12-19 | 2004-12-16 | Zaloga Gary P. | Fatty acid phenolic conjugates |
AU2003288606A1 (en) * | 2002-12-20 | 2004-07-14 | Pronova Biocare As | Use of a fatty acid composition for treatment of male infertility |
SE0303513D0 (sv) * | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
GB0403247D0 (en) * | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
GB0413730D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
GB0413729D0 (en) | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
KR20070038553A (ko) * | 2004-08-06 | 2007-04-10 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 신규한 스타틴 약제학적 조성물 및 관련된 치료방법 |
KR20070052760A (ko) * | 2004-08-06 | 2007-05-22 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 신규한 페노피브레이트 제제 및 관련된 치료방법 |
US20090030077A1 (en) * | 2004-08-06 | 2009-01-29 | Transform Pharmaceuticals Inc. | Novel Fenofibrate Formulations and Related Methods of Treatment |
ZA200702216B (en) * | 2004-08-18 | 2008-11-26 | Ace Aps | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists |
US20060051462A1 (en) * | 2004-09-03 | 2006-03-09 | Wang Jimmy X | Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients |
CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
GB0428384D0 (en) * | 2004-12-24 | 2005-02-02 | Sla Pharma Ag | Eicosapentaenoic acid |
JP5503846B2 (ja) * | 2005-01-24 | 2014-05-28 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、dhaを含有する脂肪酸組成物の使用 |
BRPI0607569A2 (pt) | 2005-03-08 | 2009-09-15 | Reliant Pharmaceuticals Inc | composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária |
KR101465715B1 (ko) | 2005-07-08 | 2014-11-27 | 모치다 세이야쿠 가부시키가이샤 | 심혈관 이벤트 발병 예방용 조성물 |
ITMI20051560A1 (it) * | 2005-08-10 | 2007-02-11 | Tiberio Bruzzese | Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6 |
US7652068B2 (en) | 2005-12-20 | 2010-01-26 | Cenestra Llc | Omega 3 fatty acid formulations |
CA2641852A1 (en) | 2006-02-10 | 2007-08-16 | Sportscom Danmark Aps | Coated tablets, their methods of preparation, and related uses |
MY153288A (en) | 2006-06-28 | 2015-01-29 | Hovid Berhad | An effective pharmaceutical carrier for poorly bioavailable drugs |
WO2008011179A2 (en) | 2006-07-21 | 2008-01-24 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids for use in treating resistant hypertension |
EP2068861A4 (en) * | 2006-07-21 | 2010-01-06 | Reliant Pharmaceuticals Inc | COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND USE THEREOF IN THE TREATMENT OF PERIPHERAL ARTERIES DISEASE AND INTERMITTENT CLAUDICATION |
US7676518B2 (en) | 2006-08-16 | 2010-03-09 | Sap Ag | Clustering for structured data |
WO2008088415A1 (en) * | 2006-10-18 | 2008-07-24 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids for reduction of lp-pla2 levels |
WO2008113177A1 (en) * | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
JP2010521534A (ja) | 2007-03-23 | 2010-06-24 | ノバルティス アーゲー | 黄斑変性を処置するためのマスクまたはコーティング銅塩の使用 |
US20080261896A1 (en) * | 2007-04-11 | 2008-10-23 | Sinphar Pharmaceutical Co., Ltd. | Testosterone generating and metabolizing enhancer |
WO2009009040A2 (en) | 2007-07-06 | 2009-01-15 | Baum Seth J | Fatty acid compositions and methods of use |
US8370627B2 (en) | 2008-01-04 | 2013-02-05 | University Of Yamanashi | Confidential communication method |
EP2455071A1 (en) | 2008-01-10 | 2012-05-23 | Takeda Pharmaceutical Company Limited | Capsule Formulation |
US20100062057A1 (en) | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
WO2010040012A1 (en) | 2008-10-01 | 2010-04-08 | Martek Biosciences Corporation | Compositions and methods for reducing triglyceride levels |
US11395811B2 (en) * | 2009-03-09 | 2022-07-26 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture comprising EPA and DHA in free acid form and a surfactant, and methods and uses thereof |
EP2488022B1 (en) | 2009-10-16 | 2018-01-10 | Mochida Pharmaceutical Co., Ltd. | Compositions |
JP6116905B2 (ja) | 2009-10-23 | 2017-04-19 | プロノヴァ・バイオファーマ・ノルゲ・アーエスPronova BioPharma Norge AS | 脂肪酸油混合物の被覆型カプセル剤および錠剤 |
-
2010
- 2010-03-09 US US13/255,587 patent/US11395811B2/en active Active
- 2010-03-09 WO PCT/IB2010/000788 patent/WO2010119319A1/en active Application Filing
- 2010-03-09 BR BRPI1009431A patent/BRPI1009431A2/pt not_active Application Discontinuation
- 2010-03-09 CN CN201910497672.0A patent/CN110538148A/zh active Pending
- 2010-03-09 JP JP2011553553A patent/JP6176894B2/ja active Active
- 2010-03-09 ES ES10750438T patent/ES2894340T3/es active Active
- 2010-03-09 MX MX2011009503A patent/MX2011009503A/es unknown
- 2010-03-09 EA EA201171113A patent/EA022028B1/ru not_active IP Right Cessation
- 2010-03-09 AU AU2010222648A patent/AU2010222648B2/en active Active
- 2010-03-09 WO PCT/IB2010/000824 patent/WO2010103404A1/en active Application Filing
- 2010-03-09 US US13/255,602 patent/US9532963B2/en active Active
- 2010-03-09 EP EP10750438.3A patent/EP2405902B1/en active Active
- 2010-03-09 NZ NZ595204A patent/NZ595204A/en unknown
- 2010-03-09 WO PCT/IB2010/000791 patent/WO2010103402A1/en active Application Filing
- 2010-03-09 CA CA2754860A patent/CA2754860C/en active Active
- 2010-03-09 EP EP10764152.4A patent/EP2405903B1/en active Active
- 2010-03-09 KR KR1020187007824A patent/KR101966874B1/ko active IP Right Grant
- 2010-03-09 US US13/255,595 patent/US11612579B2/en active Active
- 2010-03-09 EP EP10750436.7A patent/EP2405895B1/en active Active
- 2010-03-09 CN CN201410322762.3A patent/CN104146955A/zh active Pending
- 2010-03-09 EP EP21186673.6A patent/EP3915554A1/en active Pending
- 2010-03-09 ES ES10750436T patent/ES2881885T3/es active Active
- 2010-03-09 KR KR1020117023450A patent/KR101841756B1/ko active IP Right Grant
- 2010-03-09 PH PH12019500030A patent/PH12019500030A1/en unknown
- 2010-03-09 CN CN2010800203059A patent/CN102421422A/zh active Pending
- 2010-03-09 KR KR1020197009512A patent/KR102118478B1/ko active IP Right Grant
- 2010-03-09 SG SG2011065075A patent/SG174314A1/en unknown
- 2010-03-09 CA CA3065860A patent/CA3065860A1/en not_active Abandoned
-
2011
- 2011-09-08 IL IL215043A patent/IL215043A/en not_active IP Right Cessation
- 2011-10-03 CO CO11130069A patent/CO6501136A2/es not_active Application Discontinuation
-
2015
- 2015-12-25 JP JP2015253166A patent/JP6723009B2/ja active Active
-
2016
- 2016-11-14 US US15/350,522 patent/US10028928B2/en active Active
-
2018
- 2018-02-05 JP JP2018018093A patent/JP2018090600A/ja active Pending
- 2018-07-23 US US16/043,097 patent/US10596142B2/en active Active
-
2020
- 2020-02-06 JP JP2020018504A patent/JP7199389B2/ja active Active
- 2020-03-24 US US16/828,062 patent/US11523999B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500030A1 (en) | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof | |
MX2011009507A (es) | Emulsiones de aceite en agua a base de pescado enriquecidas en omega-3 para nutricion parenteral. | |
DE602007013611D1 (es) | ||
NZ716730A (en) | Methods, compositions, and devices for supplying dietary fatty acid needs | |
EA201170433A1 (ru) | Полисахаридная капсула, включающая в себя эмульсию, содержащую масло жирных кислот | |
EA201600471A1 (ru) | Экстрагированный растительный липид, содержащий длинноцепочечные полиненасыщенные жирные кислоты | |
MX2010004820A (es) | Mezcla lipidica para nutricion infantil. | |
FR2955459B1 (fr) | Composition huileuse riche en monoglycerides de dha | |
CO6470849A2 (es) | Proceso para la obtención de un concentrado de ésteres de ácidos eicosapentaenoico y docosahexaenoico | |
MX2012005744A (es) | Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. | |
EP2506848A4 (en) | SUBSTANCES TO REDUCE THE IMPACT OF HARD CARDIAL EVENTS CONTAINING AN EXTRACT OF RED FERMENTED RICE AND A MULTIPLE UNSATURATED OMEGA-3 FATTY ACID OR DERIVATIVES THEREOF | |
MX335992B (es) | Composiciones de grasa solida que contiene un acido graso poliinsaturado y usos y produccion de las mismas. | |
NZ612214A (en) | Nutritional products including monoglycerides and fatty acids | |
MX2013010076A (es) | Composiciones y metodos que comprenden c16:1n7 palmitoleato. | |
MX2014000770A (es) | Composiciones de acidos grasos. | |
MY162872A (en) | Oil and fat composition, bakery food using oil and fat composition, and composite food using bakery food | |
WO2011149854A3 (en) | Stable formulations of fatty acids | |
WO2011106618A8 (en) | Balanced myristate- and laurate-containing edible oil | |
CL2010001587A1 (es) | Proceso de preparacion de un concentrado de etil esteres de acidos grasos omega-3 que comprende sobre el 80% en peso de dichos esteres en configuracion cis y sus dobles enlaces separados por una unidad metilenica. | |
MX364687B (es) | Composicion de microemulsion de ac/ag. | |
MY159390A (en) | Nutritional composition for infants | |
MX2012001718A (es) | Composicion farmaceutica que incluye un ester de dha para ser administrada parenteralmente. | |
WO2012153345A9 (en) | Docosahexaenoic acid (dha) as polyunsaturated free fatty acid in its directly compressible powder form and method of isolation thereof | |
MY170462A (en) | Composition | |
PE20130985A1 (es) | Procedimiento para obtener esteres alquilicos de acidos grasos a partir de lipidos en un contactor de membrana |